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A B S T R A C T
Background: In animal models of acute myocardial infarction, n-3 polyunsaturated fatty acids (PUFAs)
administered before coronary occlusion have been suggested to prevent induction of ventricular
arrhythmia and limit infarct size. However, the relation between the serum levels of n-3 PUFAs and
ischemia/reperfusion (I/R) injury remains unclear.
Methods: 211 patients with ST-segment elevation acute myocardial infarction received emergency
percutaneous coronary intervention (PCI) within 6 h from the onset. The patients were divided into two
groups according to the sum of serum eicosapentaenoic acid (EPA) levels and docosahexaenoic acid
(DHA) levels before PCI: group L (n = 106), EPA + DHA <155 mg/ml and group H (n = 105), EPA + DHA
155 mg/ml. The Selvester QRS-scoring system was used to estimate the serial change in infarct size.
Results: Time to reperfusion was similar between the 2 groups. The QRS score before PCI was higher in
group L than in group H (2.42  2.00 vs 1.85  2.01, p = 0.015). The proportion of patients with I/R injury
immediately after reperfusion, deﬁned as reperfusion ventricular arrhythmias (25% vs 11%, p = 0.006) and ST-
segment re-elevation (44% vs 22%, p < 0.001), was also higher in group L than in group H, followed by a
greater increment in the QRS score during PCI (3.51  2.51 vs 2.54  1.91, p = 0.006) and higher peak levels of
creatinine phosphokinase (3552  241 U/L vs 2660  242 U/L, p < 0.01). On multivariate analysis, serum
level of EPA + DHA was an independent predictor of reperfusion injury (odds ratio 0.985, p = 0.032).
Conclusion: Serum level of n-3 PUFAs before PCI may be a predictor of I/R injury and the resultant extent
of myocardial damage. These ﬁndings suggest a protective effect of serum n-3 PUFAs on ischemic
myocardium.
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Although the restoration of blood ﬂow to the jeopardized
myocardium is a prerequisite for myocardial salvage, reperfusion
itself may either directly accelerate ischemia or additionally injure
the myocardium, a phenomenon referred to as ‘‘myocardial
reperfusion injury’’ [1], which is reported to account for up to
50% of ﬁnal infarct size in acute myocardial infarction (AMI)
[2]. Ventricular arrhythmias and additional ST-segment elevation reserved.
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caused directly by the reperfusion process, have previously been
shown to result in a larger extent of myocardial infarct [3–
8]. Demonstration of the beneﬁcial ischemic preconditioning
induced by pharmacological agents or noninvasive devices has
regenerated interest in reperfusion phase as a target for
cardioprotection [9–11].
A large amount of evidence from clinical outcomes has
suggested an increased intake of n-3 polyunsaturated fatty acids
(PUFAs), especially eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA) has cardioprotective effects and reduces
cardiovascular mortality [12–14]. The analysis of these trials has
concluded that these beneﬁcial effects mainly occur through the
prevention of sudden cardiac death (SCD), which is often
associated with ventricular arrhythmias, indicating that n-3 PUFAs
are antiarrhythmic [15]. On the other hand, there are several
experimental studies demonstrating that n-3 PUFAs, when
administered prior to coronary occlusion, attenuate the severity
of myocardial ischemia/reperfusion (I/R) injury and limit infarct
size in a concentration-dependent manner [16,17]. However, the
functional role of preexisting serum n-3 PUFAs in reperfusion
injury remains unclear, especially in humans. To gain insights into
this issue, the present study investigated the relations of serum n-3
PUFAs levels to lethal reperfusion injury and infarct size in patients
with ST-segment elevation acute myocardial infarction (STEMI)
who underwent percutaneous coronary intervention (PCI).
Methods
Subjects
From March 1, 2009 through February 28, 2014, a total of
230 consecutive patients with STEMI received emergency PCI
within 6 h from the onset of chest pain. Inclusion criteria for this
study were (1) continuous chest pain lasting for >30 min, (2) ST-
segment elevation of 0.1 mV in 2 or more contiguous leads on 12-
lead electrocardiograms (ECG), (3) angiographically conﬁrmed
culprit lesion with diameter stenosis of 90% and Thrombolysis In
Myocardial Infarction (TIMI) ﬂow grade of 0 or 1, and (4) a
subsequent increase in the serum creatinine phosphokinase (CPK)
level to more than 2 times the upper limit of normal.
A total of 19 patients were excluded: 5 with ventricular
ﬁbrillation on the initial ECG recorded at the scene who received
pre-hospital cardiopulmonary resuscitation, 1 with pacing rhythm,
10 with a history of previous AMI, 2 with cardiac rupture, and 1 in
whom PCI was unsuccessful because these conditions have been
linked to infarct size. Data on the remaining 211 patients with
STEMI were included in the ﬁnal analysis [160 men, 51 women;
age, 67  13 (mean  SD) years]. All patients gave written consent to
undergo PCI.
Procedure of percutaneous coronary intervention
PCI was performed after intravenous administration of 8000 IU
heparin using a 6- or 7-French sheath and catheter. Antiplatelet
therapy before PCI consisted of aspirin and clopidogrel. Prepro-
cedural nicorandil was used at the operator’s discretion. After
crossing the target lesion with the guidewire, coronary thrombus
aspiration was performed. Bare metal stents were implanted in
patients with suboptimal results after balloon angioplasty.
Assessment of reperfusion injury by ST-segment re-elevation and
reperfusion arrhythmias
Standard 12-lead ECGs were recorded just before recanaliza-
tion, immediately after reperfusion (when there is TIMI II-III ﬂowin the distal vessel), and 1 h after recanalization. ST-segment
elevation was measured 80 ms after the J point by 2 independent
observers who were blinded to all clinical and angiographic
ﬁndings. We deﬁned reperfusion injury as ST-segment re-elevation
or ventricular arrhythmias (or both) occurring just after the time
there was established TIMI II-III ﬂow, but not that after balloon
inﬂation or stent implantation. Additional ST-segment elevation of
at least 5 mm in leads V1–6, I, and aVL for anterior AMI and in leads
II, III, aVF for non-anterior AMI immediately after reperfusion was
deﬁned as ST-segment re-elevation [18]. Ventricular arrhythmias
included accelerated idioventricular rhythm (AIVR), ventricular
tachycardia, and ventricular ﬁbrillation (VF) [1]. Additionally, the
sum of the ST-segment elevations in 3 contiguous leads with the
highest ST-segment elevations was calculated. ST-segment reso-
lution was deﬁned as a reduction of at least 50% in ST-segment
elevation on ECGs obtained 1 h after recanalization compared with
the initial value [19]. Myocardial blush grade after PCI was
determined using a previously reported grading scale [20].
Assessment of infarct size
Blood samples were obtained on admission and at 3-h intervals
until the CPK level reached peak value. We analyzed the sum of
CPK level during 48 h with at least six blood samples and used it as
an enzymatic marker of ﬁnal infarct size as well as the peak CPK
level. In addition, ECGs were scored according to the 32-point
Selvester QRS scoring system before, 1 h after recanalization, and
at discharge (QRSpre, QRSpost, QRSﬁnal) to estimate the serial
change in infarct size [21]. The increment in QRS score during PCI
(QRSpost  QRSpre) reﬂects the amount of myocardial damage
related to reperfusion injury [22]. QRSﬁnal was used as another
marker of ﬁnal infarct size.
Quantiﬁcation of myocardial area at risk
Myocardial area at risk was estimated angiographically using a
modiﬁed version of the Alberta Provincial Project for Outcome
Assessment in Coronary Heart Disease (APPROACH-modiﬁed
score) [23].
Measurement of serum fatty acids levels
Blood samples for measurement of serum fatty acids levels
were obtained prior to angiography, with the patient in a supine
position. The serum fatty acid composition was determined by
capillary gas chromatography using the Shimadzu GC-17A gas
chromatograph (Shimadzu, Kyoto, Japan) and the BPX70 capillary
column (SGE International, Melbourne, Australia).
Statistical analysis
Data are expressed as means  standard deviation (SD) for
continuous variables and as percentages for categorical variables. To
test for statistical signiﬁcance, continuous variables were compared
using Student’s t-test, and categorical data were compared using the
chi-square test. Study variables included baseline clinical character-
istics (age, gender, drugs, coronary risk factors, time to reperfusion,
location of culprit lesion, previous angina, absence of collateral ﬂow,
multivessel disease, QRSpre, and preprocedural injection of nicor-
andil) and serum EPA + DHA levels before PCI. Univariate analysis
and multivariate analysis were performed by logistic regression to
determine independent predictors of reperfusion injury as deﬁned by
reperfusion ventricular arrhythmias, ST-segment re-elevation, or
both. In this analysis, factors associated with the dependent variable
at p < 0.20 on univariate analysis were entered into the multivariate
model and eliminated using a backward procedure. Additionally,
K. Arakawa et al. / Journal of Cardiology 66 (2015) 101–107 103receiver-operating characteristic (ROC) curves were analyzed to
assess the cut-off value of serum EPA + DHA levels for the best
prediction of reperfusion injury. The optimal cut-off value was
deﬁned as the value giving the maximal sum of sensitivity and
speciﬁcity. All p-values of <0.05 were considered to indicate
statistical signiﬁcance. All analyses were performed using JMP
9.1 software (SAS Institute Inc., Cary, NC, USA).
Results
The patients were divided into two groups on the basis of the
sum of serum EPA and DHA levels before angiography (median,
155.0 mg/ml): group L (n = 106), EPA + DHA <155.0 mg/ml, and
group H (n = 105), EPA + DHA 155.0 mg/ml.
Comparisons of patients’ characteristics and angiographic ﬁndings
Clinical characteristics and angiographic ﬁndings are summa-
rized in Table 1. As compared with group H, group L had higher
proportions of patients with male sex and current smoking. Group
L also had lower proportions of patients who were receiving
calcium antagonists. Patients in group L had lower arachidonic acid
(AA) level and a tendency toward younger age. There was noTable 1
Baseline clinical characteristics and coronary angiographic ﬁndings.
Group L 
EPA + DHA < 155 mg/ml (n = 1
Age (years) 64.6  11.7 
Gender (male, n (%)) 82 (82%) 
Coronary risk factors, n (%)
Hypertension 55 (55%) 
Diabetes mellitus 33 (33%) 
Dyslipidemia 76 (76%) 
Smoking 52 (52%) 
Family history of CAD 27 (23%) 
Drugs, n (%)
Anticoagulant 9 (9%) 
Statins 16 (16%) 
ACE-I/ARB 20 (20%) 
Ca-antagonists 19 (19%) 
b-Blockers 5 (5%) 
Nitrates 3 (3%) 
Laboratory data (peripheral blood)
WBC (/mL) 10,173  3176 
Creatinine (mg/dl) 0.898  0.259 
hs-CRP (mg/dl) 0.353  0.716 
Glucose (mg/dl) 169  66 
Fatty acids
EPA (mg/ml) 30.2  3.3 
AA (mg/ml) 145.6  47.8 
DHA (mg/ml) 80.0  18.9 
DHLA (mg/ml) 34.2  15.2 
EPA/AA ratio 0.22  0.13 
Pre-MI angina, n (%) 54 (54%) 
Time to sampling (h) 2.37  1.32 
Time to reperfusion (h) 3.17  1.30 
Preprocedural nicorandil, n (%) 6 (6%) 
Killip Score 1 vs 2/3/4, n (%) 77/23 (77/23%) 
RCA/LAD/LCX, n (%) 39/45/16 (39/45/16%) 
Multivessel disease, n (%) 46 (46%) 
Rentrop’s collateral grade 2 or 3, n (%) 36 (36%) 
Myocardial area at risk (%LV) 25.9  12.6 
Final TIMI 3, n (%) 92 (92%) 
Systolic BP (mmHg) 146  34 
Heart rate (beats/min) 76  18 
Values are mean  SD or median value (25th to 75th percentile range) or n (%). CAD, corona
II receptor blockers; WBC, white blood cell; CRP, C-reactive protein; EPA, eico
dihomogammalinolenic acid; MI, myocardial infarction; RCA, right coronary artery; LAD,
myocardium; TIMI, thrombolysis in myocardial infarction; BP, blood pressure.correlation between the serum EPA + DHA levels and the time to
blood sampling after symptom onset in the study group (Fig. 1).
Reperfusion injury and impaired myocardial damage
I/R injury immediately after reperfusion, deﬁned as reperfusion
ventricular arrhythmias (25% vs 11%, p = 0.006) and ST-segment
re-elevation (44% vs 22%, p < 0.001), occurred in a higher
proportion of patients in group L than in group H (Fig. 2). The
serial change in the QRS score is shown in Fig. 3. Despite similar
reperfusion time, QRS score before PCI was higher in group L than
in group H (2.42  2.00 vs 1.85  2.01, p = 0.015). Additionally, the
increment in QRS score during PCI (QRSpost  QRSpre) was
signiﬁcantly greater (3.51  2.51 vs 2.44  1.41, p < 0.001), followed
by the more magniﬁed difference in QRS score 1 h after recanalization
between group L and group H (5.92  3.78 vs 4.22  3.09, p < 0.001).
As well, the QRS score at discharge was also signiﬁcantly higher in
group L (6.01  3.69 vs 4.44  3.11, p = 0.001). There was no
signiﬁcant change in QRS score (from QRSpost to QRSﬁnal) between
the 2 groups.
Group L had a higher proportion of patients with a myocardial
blush grade of 0 or 1 (50% vs 34%, p = 0.024). There was a tendency
toward a higher proportion of no ST-segment resolution in group L
than in group H (35% vs 24%, p = 0.092). Peak CPK levelGroup H p-value
06) EPA + DHA  155 mg/ml (n = 105)
68.0  13.7 0.060
69 (66%) 0.052
64 (64%) 0.259
33 (33%) 1.000
86 (86%) 0.184
29 (29%) 0.002
23 (23%) 0.487
13 (13%) 0.366
19 (19%) 0.576
29 (29%) 0.138
33 (33%) 0.015
3 (3%) 0.468
3 (3%) 1.000
9456  2771 0.094
0.853  0.298 0.249
0.289  0.253 0.167
167  57 0.738
83.7  3.3 <0.001
164.9  56.5 0.01
154.0  41.6 <0.001
34.3  12.8 0.965
0.55  0.34 <0.001
45 (45%) 0.178
2.64  1.42 0.420
3.19  1.37 0.888
7 (7%) 0.789
89/11 (89/11%) 0.235
46/41/13 (46/41/13%) 0.467
54 (54%) 0.373
34 (34%) 0.582
26.1  11.1 0.918
91 (91%) 0.723
147  42 0.973
72  19 0.076
ry artery disease; ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin
sapentaenoic acid; AA, arachidonic acid; DHA, docosahexaenoic acid; DHLA,
 left coronary artery; LCX left circumﬂex; %LV, the percentage of the left ventricular
Fig. 3. Serial changes in QRS score. Data are presented as means  SD. QRSpre, QRS
score before recanalization; QRSpost, QRS score 1 h after recanalization; QRSﬁnal, QRS
score at discharge.
Fig. 1. Association between the serum EPA + DHA levels before PCI and the time to
blood sampling. There was no correlation between the serum EPA + DHA levels and
the time to blood sampling up to 6 h after symptom onset in the study group. EPA,
eicosapentaenoic acid; DHA, docosahexaenoic acid.
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during 48 h (76,968.8  5130 U/L h vs 63,563.3  5579.5 U/L h,
p = 0.0487) were signiﬁcantly higher in group L than in group H.
Clinical prediction of reperfusion injury
To investigate which clinical variables and risk factors were
associated with I/R injury as deﬁned by the occurrence of
reperfusion ventricular arrhythmias, ST-segment re-elevation,
or both, we performed univariate and multivariate analyses
(Table 2). Serum EPA + DHA levels, pre-myocardial infarction
angina, and time to reperfusion were found to be independent
predictors of I/R injury.
The discriminative performance of n-3 PUFAs for predicting
reperfusion injury was determined on ROC curve analysis (Fig. 4).
We found that the serum EPA + DHA levels <135.4 mg/ml
predicted reperfusion ventricular arrhythmia most effectively,
with a sensitivity of 66% and a speciﬁcity of 64%, respectively. The
area under the curve (AUC) was 0.643 (p = 0.018). Similarly, the
optimal cutoff value of the serum EPA + DHA levels for ST-segmentFig. 2. Comparison of ischemia/reperfusion injury immediately after reperfusion betwee
elevation. The solid bars indicate the proportion of patients with ventricular arrhythmre-elevation was 157.4 mg/ml, with a sensitivity of 72% and a
speciﬁcity of 56%, respectively (AUC 0.614, p = 0.009).
Discussion
To our knowledge, this is the ﬁrst study to analyze the
association between n-3 PUFA levels before PCI and myocardial
damage, including reperfusion injury immediately after myocar-
dial reperfusion in patients with STEMI who underwent PCI. The
major ﬁndings of the present study are as follows: (1) in patients
with lower serum EPA + DHA level, preexisting myocardial damage
before PCI was greater; and (2) independent of pre-myocardial
infarction angina, a lower serum EPA + DHA level before angiogra-
phy was associated with a higher rate of reperfusion injury, as well
as a greater extent of myocardial infarction during PCI.
In the setting of reperfused myocardial infarction, not only an
additional increase in ST-segment shift during reperfusion, but also
ventricular arrhythmias are associated with delayed microvascular
reperfusion, larger infarct size, and further worsening of left
ventricular function after the acute phase [3–8], even after
successful epicardial reperfusion. These phenomena, shown justn group L and H. (Right) Reperfusion ventricular arrhythmia. (Left) ST-segment re-
ias and ST-segment re-elevation.
Table 2
Logistic regression analysis for myocardial reperfusion injury.
Univariate analysis Multivariate analysis
Odds ratio (95% CI) p-value Odds ratio (95%CI) p-value
Age (years) 1.021 (0.998–1.044) 0.074 1.017 (0.992–1.043) 0.178
Gender (male, n (%)) 0.773 (0.391–1.494) 0.446
Hypertension 0.880 (0.549–1.413) 0.596
Diabetes mellitus 1.520 (0.891–1.955) 0.258
Dyslipidemia 1.608 (0.761–2.515) 0.270
Smoking 1.850 (0.803–3.358) 0.081
Family history of CAD 1.369 (0.717–2.612) 0.339
Anticoagulants 1.411 (0.575–3.465) 0.448
Statins 1.556 (0.746–3.261) 0.237
ACE-I/ARB 0.732 (0.370–1.408) 0.351
Ca-antagonists 0.531 (0.265–1.128) 0.187 0.540 (0.252–1.121) 0.109
b Blockers 0.727 (0.167–3.158) 0.659
Nitrates 0.265 (0.014–1.670) 0.210
Anterior AMI 1.555 (0.882–2.655) 0.137 1.249 (0.615–2.540) 0.538
Pre-MI angina 0.518 (0.323–0.826) 0.006 0.510 (0.269–0.950) 0.039
Time to reperfusion (h) 0.798 (0.634–1.003) 0.052 0.709 (0.544–0.965) 0.038
Multivessel disease 0.875 (0.466–1.632) 0.875
Preprocedural nicorandil 0.589 (0.155–1.878) 0.370
Serum EPA + DHA level (mg/ml) 0.993 (0.990–0.996) 0.003 0.985 (0.989–0.9970) 0.032
Absence of collateral ﬂow 0.796 (0.428–1.444) 0.446
QRSpre 1.136 (1.007–1.287) 0.038 1.141 (0.973–1.346) 0.105
CAD, coronary artery disease; ACE-I, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; AMI, acute myocardial infarction; QRSpre, QRS
score before recanalization; EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid.
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reperfusion at the myocardial level.
N-3 PUFAs are essential nutrients that must be acquired from
the diet and are required for normal cellular function [24]. Several
experimental studies have demonstrated that dietary supplemen-
tation of ﬁsh oil attenuates myocardial infarct size and dysfunction
induced by ischemia and reperfusion, as well as lethal ventricular
arrhythmias [17]. With unique chemical structures and 3-
dimensional conﬁgurations, n-3 PUFAs inﬂuence several relevant
molecular pathways of I/R injury [24]. First, n-3 PUFAs directly
inﬂuence ventricular myocyte electrophysiology, potentially
mediated by effects on membrane ion channels or cell to cell
connections [24]. N-3 PUFAs might inhibit the L-type Ca2+ current,
thereby reducing the cytosolic Ca2+ ﬂuctuations that trigger
arrhythmias, and the voltage-dependent Na+ current thatFig. 4. Receiver-operating characteristic curve for predicting reperfusion injury in rela
angiography. (Right) Reperfusion ventricular arrhythmia. (Left) ST-segment re-elevatiodecreases the resting membrane potential. Additionally, n-3
PUFAs ameliorate ischemia-induced shortening of monophasic
action potential, followed by suppression of prolonged QT interval,
particularly in the setting of acute ischemia, that is a multi-channel
blocker [25,26]. Second, n-3 PUFAs might improve autonomic
function, especially related to augmentation of vagal activity or
tone [24], which increased the threshold of VF. Besides, the
beneﬁcial effects of ﬁsh oil on myocardial I/R injury are partially
associated with its antithrombotic property as a result of altered
platelet function, anti-inﬂammatory effects, or vasoactive effects
via increased production of nitric oxide in endothelial cells [27–
30]. Furthermore, pretreatment with n-3 PUFAs induces a form of
preconditioning and endows cardioprotection as powerful as
ischemic preconditioning, which provides no additional protection
on n-3 PUFA feeding [31]. These mechanisms might individually ortion to the serum eicosapentaenoic acid and docosahexaenoic acid levels before
n. AUC, area under the curve.
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injuries.
There are numerous experimental studies in both animals and
humans demonstrating that even a modest increase in n-3 PUFAs
might have an important local function against fatal cardiac
arrhythmias. Modest ﬁsh oil consumption was reported to increase
myocardial membrane n-3 fatty acid levels more than twice,
indicating strong preferential incorporation of dietary n-3 fatty
acids into heart tissue [32]. On the other hand, the different effects
of ﬁsh oil consumption on different cardiovascular outcomes is
likely related to varying dose-responses and time-responses of the
effects of n-3 PUFAs on different cardiovascular risk factors. At
typical dietary intakes within weeks to months (e.g. <750 mg/day
of EPA + DHA), antiarrhythmic effects predominate, whereas a
reduction in atherosclerosis or nonfatal MI may be modestly
reduced by only higher doses or more prolonged intake [33]. This
difference might be made by n-3 PUFA-derived eicosanoids, which
possess nearly 1000-fold greater potency than their parent n-3
PUFAs in reducing effects of calcium overload in ventricular
myocytes [34].
Parenteral n-3-enriched lipid emulsions have been established
for many years to be safe and beneﬁcial in the clinical conditions
characterized by an inﬂammatory over-response [35]. As men-
tioned above, patients with AMI are relatively sensitive to anti-
arrhythmic effects of n-3 PUFAs [36]. In line with this notion, our
results suggest that acute administration of n-3 PUFAs before or
during PCI in patients with AMI might be an adjunctive therapy,
especially in patients with low serum n-3 PUFA levels, and provide
cardioprotection against ischemic reperfusion injury.
In some experiments of cellular models, EPA and DHA
possessed different potency of effects depending upon the target
ion channel [37]. Nonetheless, data are insufﬁcient on relative
importance of EPA versus DHA or any speciﬁc ‘‘ratio’’ of their
intakes. The present study suggests that EPA and DHA have both
shared and complementary beneﬁts. Increasing consumption
of either would be most prudent compared to little or no
consumption.
Some clinical trials indicate that ﬁsh oil does not confer
protection against recurrent ventricular arrhythmia in patients
with an implantable cardioverter deﬁbrillator [38]. However,
participants in these trials were already taking more concomitant
cardioprotective therapies than those with ﬁrst AMI, including the
present study. That is another reason patients with ﬁrst AMI are
likely to beneﬁt from possible antiarrhythmic effect of n-3 PUFAs.
Study limitation
First, since this was an observational study, the precise
mechanisms that lower values of n-3 PUFAs associated with the
more frequent occurrence of reperfusion injury, remain to be
elucidated. Second, patient characteristics were not totally
matched between the two groups. However, multivariate analysis
showed none of them, except for n-3 PUFAs, previous angina, and
reperfusion time were independently associated with myocardial
reperfusion injury. Third, QRSpre was not an associated variable on
multivariate analysis, which is inconsistent with a previous study
showing high QRSpre was predictive of no-reﬂow [39]. This might
be because reperfusion time, which was signiﬁcantly correlated
with QRSpre, was included as a study variable on our multivariate
analysis, although it was not included on the previous one. Fourth,
the AUC in prediction of reperfusion injury was not so high. From a
molecular point of view, there are various types of inﬂammatory
mediators involved in a complex interaction between platelets,
neutrophils, and endothelium [40,41]. Moreover, n-3 PUFA-
derived eicosanoids, which possessed nearly 1000-fold greater
potency than their parent n-3 PUFAs, and genetic predispositionwere not considered in the present study [42]. These factors might
inﬂuence the effect of n-3 PUFAs.
Conclusion
Serum level of EPA + DHA before PCI may be a predictor of
ischemia/reperfusion injury immediately after myocardial reper-
fusion and the resultant extent of myocardial damage. Our ﬁndings
indicate the clinical importance of a protective effect of n-3 PUFAs
on ischemic myocardium.
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